Overview

Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
0
Participant gender:
Female
Summary
To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Mexiletine
Criteria
Inclusion Criteria:

- Established IBS diagnosis with a known A997T mutation in NaV1.5T

Exclusion Criteria:

- Normal 48-hour baseline transit study

- Current use of mexiletine

- Inability to stay in Rochester for 9 days for testing

- Known allergy to mexiletine

- Inability to complete daily diary

- Taking a medication known to affect myotonia, had a coexisting neuromuscular disease,
or had another serious medical illness including second- or third-degree heart block,
atrial flutter, atrial fibrillation, ventricular arrhythmia, history of cardiac
arrhythmia requiring medication, congestive heart failure, symptomatic cardiomyopathy,
or symptomatic coronary artery disease

- Inability to withdraw medications known to interact with mexiletine. Patient is
currently not on any of these medications